The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

by Hage, C, Rausch, V, Giese, N, Giese, T, Schönsiegel, F, Labsch, S, Nwaeburu, C, Mattern, J, Gladkich, J, Herr, I
Published 2013

Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas

by Salnikov, A V, Bretz, N P, Perne, C, Hazin, J, Keller, S, Fogel, M, Herr, I, Schlange, T, Moldenhauer, G, Altevogt, P
Published 2013

Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy

by Fan, P, Zhang, Y, Liu, L, Zhao, Z, Yin, Y, Xiao, X, Bauer, N, Gladkich, J, Mattern, J, Gao, C, Schemmer, P, Gross, W, Herr, I
Published 2016

Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib

by Liu, L, Aleksandrowicz, E, Fan, P, Schönsiegel, F, Zhang, Y, Sähr, H, Gladkich, J, Mattern, J, Depeweg, D, Lehner, B, Fellenberg, J, Herr, I
Published 2014